Market Access & Reimbursement
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Market Access
To get their gene or cell therapies through health technology appraisals, companies need to agree to gather longer-term evidence, be upfront about what treatments can really deliver and remember to ask for patient input.
US HHS secretary tells Senate Finance Committee he believes pharmacy benefit managers will effectively keep drug costs down in Medicare Part D, even without rebates.
Novartis and German insurers have agreed a payment by outcomes deal for its CAR-T therapy Kymriah.
Without President Trump’s focus on drug pricing, it is hard to imagine that seven top industry executives would have had to face a grilling in the US Senate Finance Committee. But they can also thank Trump’s indiscretions for helping ensure that the hearing was barely even a one-day story.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.